These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 18949577

  • 1. Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.
    de Sain-van der Velden MG, Verrips A, Prinsen BH, de Barse M, Berger R, Visser G.
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S387-93. PubMed ID: 18949577
    [Abstract] [Full Text] [Related]

  • 2. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
    Clarenbach JJ, Lindenthal B, Dotti MT, Federico A, Kelleher JK, von Bergmann K.
    Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
    [Abstract] [Full Text] [Related]

  • 3. High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
    Kuriyama M, Fujiyama J, Kasama T, Osame M.
    J Lipid Res; 1991 Feb; 32(2):223-9. PubMed ID: 2066659
    [Abstract] [Full Text] [Related]

  • 4. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
    Batta AK, Salen G, Tint GS.
    Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.
    Mandia D, Chaussenot A, Besson G, Lamari F, Castelnovo G, Curot J, Duval F, Giral P, Lecerf JM, Roland D, Pierdet H, Douillard C, Nadjar Y.
    J Neurol; 2019 Aug; 266(8):2043-2050. PubMed ID: 31115677
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
    Kuriyama M, Tokimura Y, Fujiyama J, Utatsu Y, Osame M.
    J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
    [Abstract] [Full Text] [Related]

  • 11. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis.
    Salen G, Batta AK, Tint GS, Shefer S.
    Metabolism; 1994 Aug; 43(8):1018-22. PubMed ID: 8052141
    [Abstract] [Full Text] [Related]

  • 12. Treatment and follow-up of children with cerebrotendinous xanthomatosis.
    van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ.
    Eur J Pediatr; 1998 Apr; 157(4):313-6. PubMed ID: 9578968
    [Abstract] [Full Text] [Related]

  • 13. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
    Heller R, Grau AJ, Schäbitz WR, Schwaninger M.
    Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis.
    Stelten BML, Bonnot O, Huidekoper HH, van Spronsen FJ, van Hasselt PM, Kluijtmans LAJ, Wevers RA, Verrips A.
    J Inherit Metab Dis; 2018 Jul; 41(4):641-646. PubMed ID: 28894950
    [Abstract] [Full Text] [Related]

  • 16. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
    Salen G, Berginer V, Shore V, Horak I, Horak E, Tint GS, Shefer S.
    N Engl J Med; 1987 May 14; 316(20):1233-8. PubMed ID: 3106810
    [Abstract] [Full Text] [Related]

  • 17. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
    Keren Z, Falik-Zaccai TC.
    Pediatr Endocrinol Rev; 2009 Sep 14; 7(1):6-11. PubMed ID: 19696711
    [Abstract] [Full Text] [Related]

  • 18. [Cerebrotendinous xanthomatosis].
    Burghaus L, Liu W, Haupt WF.
    Dtsch Med Wochenschr; 2007 Jul 29; 132(27):1463-6. PubMed ID: 17583829
    [Abstract] [Full Text] [Related]

  • 19. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.
    Szalat A, Gershkovich P, Ben-Ari A, Shaish A, Liberman Y, Boutboul E, Gotkine M, Hoffman A, Harats D, Leitersdorf E, Meiner V.
    Biochim Biophys Acta; 2007 Jul 29; 1771(7):839-44. PubMed ID: 17553741
    [Abstract] [Full Text] [Related]

  • 20. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
    Salen G, Steiner RD.
    J Inherit Metab Dis; 2017 Nov 29; 40(6):771-781. PubMed ID: 28980151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.